-
Phase 2
-
-
18-65Age Range
-
Active, Not Recruiting
Active, Not Recruiting
A Study of CC-99677 in Participants With Active Ankylosing Spondylitis
This study is designed to learn about response to CC-99677 treatment by measuring signs and symptoms of Ankylosing Spondylitis (AS), objective measures of disease activity, quality of life assessments, pharmacokinetics, safety, and tolerability over a 12-week double-blind period.
Inclusion Criteria: - Diagnosis of Ankylosing Spondylitis (AS) fulfilling the modified New York criteria - Active axial disease at Screening and Baseline defined by a Bath Ankylosing - Spondylitis Disease Activity Index (BASDAI) score ≥ 4 and Total Back Pain ≥ 4 - Failed prior treatment with at least 2 NSAIDs for at least 4 weeks each - Participant has never received a biologic therapy eg, tumor necrosis factor (TNF) antagonist or monoclonal antibody [mAb] against IL-17A (biologic naive main study), or have taken more than one biologic therapy (biologic-failure substudy) for the treatment of AS Exclusion Criteria: - Radiographic evidence of total ankylosis of the spine - Clinically significant back pain caused by diseases other than AS - Concurrent treatment or treatment within the 6 months prior to Baseline with cell depleting biologic agents - Participation in any study of an investigational drug, including those for COVID-19 - History of malignancy - Oral corticosteroids (prednisone or equivalent) > 10 mg/day systemically for ≥ 2 weeks prior to Baseline Visit
Experimental: Administration of CC-99677 150 mg QD PO
Experimental: Administration of CC-99677 150 mg QD PO.
Experimental: Administration of CC-99677 60mg QD PO
Experimental: Administration of CC-99677 60mg QD PO.
Placebo Comparator: Administration of Placebo QD PO
Placebo Comparator: Placebo additional dose cohort